Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure extending the disclosure postponement period, specifying the contract end date, and updating the counterparty disclosure schedule to March 8, 2033, at the customer’s request regarding the contract manufacturing agreement originally disclosed on April 26, 2019.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Single Sales and Supply Contract (Submitted on April 26, 2019)
- Reason for Correction: Extension of disclosure postponement period at the customer’s request
- Key Correction Items:
- Contract Period End Date: (Before) Unstated (-) → (After) March 8, 2033
- Disclosure Postponement Period: (Before) December 31, 2025 → (After) March 8, 2033
- Other Important Matters (Counterparty Disclosure Timeline): (Before) To be disclosed after December 31, 2025 → (After) To be disclosed after March 8, 2033
- Contract Overview (Based on Original Filing & Subsequent Amendments):
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 48,948,354,540 (USD 42,244,200, increased by USD 25,102,000 from the previous USD 17,142,200, applied exchange rate KRW 1,158.70 per USD)
- Recent Annual Revenue: KRW 535,805,801,067 (Based on FY2018 consolidated financial statements)
- Contract Amount to Revenue Ratio: 9.14%
- Counterparty: Pharmaceutical company based in Asia
- Contract Period: April 26, 2019 – March 8, 2033
- Contract Date: April 26, 2019
- Other Important Investment Details:
- The contract amount reflects an increase in total contract value from the previously disclosed amount.
- The contract end date and contract amount are subject to change upon mutual agreement.
- Counterparty identity is slated for disclosure after March 8, 2033, due to business confidentiality.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Disclosure Timeline and Contract Updates Following Postponement Extension
This correction disclosure updates the confidentiality postponement period, contract end date, and counterparty disclosure timeline for the contract manufacturing deal with an Asian pharmaceutical company to March 8, 2033.
Monitoring the adjusted disclosure schedule and potential updates to contract amounts is essential for tracking the ongoing execution of this agreement.
Relevant developments can be verified upon the expiration of the extended postponement period (March 8, 2033) or through subsequent correction disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
